Navigation Links
NxStage to Report Third Quarter Fiscal 2010 Financial Results
Date:10/11/2010

LAWRENCE, Mass., Oct. 11 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the third quarter ended September 30, 2010 on Thursday, November 4, 2010 before the opening of the financial markets.

NxStage will also host a conference call at 9:00 a.m. Eastern Time on Thursday, November 4, 2010 to discuss its third quarter financial results. To listen to the conference call, please dial 866-700-7101 (domestic) or 617-213-8837 (international).  The passcode is 22816983.   The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at www.nxstage.com/ir.cfm.

A replay of the conference call will be available 2 hours after the start of the call through November 18, 2010.  To access the replay dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 96098212.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at www.nxstage.com/ir.cfm.

About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward- looking statements. The forward-looking statements in this release include NxStage's plan to release its financial results on November 4, 2010. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, unexpected difficulty in closing the company's financial books for the quarter and other factors that are discussed in NxStage's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.Contact: Kristen K. Sheppard, Esq.VP, Investor Relationsksheppard@nxstage.com
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage(R) Secures $15 Million Revolving Line of Credit
2. NxStage(R) and Nordic Medcom Sign Distribution Agreement for the System One(TM)
3. Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM)
4. NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
5. NxStage(R) Reports Significant Interim FREEDOM Study Results
6. NxStage(R) to Report Third Quarter 2009 Financial Results
7. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
8. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
9. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
10. Virginian-Pilot Story Misleads Readers on USDA Inspection Report for PLRS
11. Reportlinker Adds European RIS/PACS Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
Breaking Medicine Technology:
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... 25, 2017 , ... Bellus Medical, a leader in medical ... new class of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream ... of aging, and minimize the appearance of pores – all with minimal downtime ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment ... can also decrease overall productivity and performance in the workplace. The goal of Clearview ... the last few weeks of April, Clearview Resolution Services will be shutting down the ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
Breaking Medicine News(10 mins):